PATIENT INFORMATION LEAFLET
Lisinopril / Hidroclorotiazida Teva-ratiopharm 20/12,5 mg tablets EFG Read this leaflet carefully before you start taking the medicine, as it contains important information for you.
1. What is Lisinopril/Hidroclorotiazida Teva-ratiopharm and for what it is used 2. What you need to know before starting to take Lisinopril/Hidroclorotiazida Teva-ratiopharm 3. How to take Lisinopril/Hidroclorotiazida Teva-ratiopharm 4. Possible side effects 5. Storage of Lisinopril/Hidroclorotiazida Teva-ratiopharm 6. Contents of the pack and additional information |
Lisinopril/Hidroclorotiazida Teva-ratiopharm belongs to the group of anti-hypertensive medications that contain an ACE inhibitor (angiotensin-converting enzyme inhibitor).
Lisinopril/Hidroclorotiazida Teva-ratiopharm contains two active substances, lisinopril and hidroclorotiazida, which lower blood pressure through different mechanisms. Lisinopril prevents the formation of hypertensive agents in the body, and hidroclorotiazida reduces blood pressure by increasing the elimination of water and salts from the body.
Lisinopril/Hidroclorotiazida Teva-ratiopharm is indicated for the treatment of hypertensionwhen the desired result has not been achieved with monotherapy alone.
Do not take Lisinopril/Hidroclorotiazida Teva-ratiopharm
Warnings and precautions
Consult your doctor or pharmacist before starting to take Lisinopril/Hidroclorotiazida ratiopharm
Your doctor may monitor your renal function, blood pressure, and electrolyte levels in your blood (such as potassium) at regular intervals.
The symptoms of angioedema include swelling of the face, lips, tongue, and/or throat with difficulty swallowing and breathing
Children and adolescents
Do not administer Lisinopril/Hidroclorotiazida ratiopharm to children under 18 years of age. There is limited information on the safety and efficacy of Lisinopril/Hidroclorotiazida in children.
Older adults
In patients over 65 years of age, blood pressure, certain laboratory values, electrolytes, creatinine, blood sugar, and hemoglobin should be monitored, especially at the beginning of treatment. Dosage should be adjusted with special care in elderly patients.
Kidney
If you have kidney insufficiency, it is essential not to take potassium supplements or potassium-sparing diuretics during treatment with lisinopril/hydrochlorothiazide, as it may increase potassium levels in your body excessively.
Surgery
Inform your doctor that you are using Lisinopril/Hidroclorotiazida Teva-ratiopharm if you need to undergo surgery (including dental surgery) during treatment, as some anesthetic agents used during surgery may cause excessive blood pressure decrease in combination with Lisinopril/Hidroclorotiazida Teva-ratiopharm.
Pregnancy
Inform your doctor if you think you are (or may be) pregnant. Lisinopril/hydrochlorothiazide is not recommended in the early stages of pregnancy, and it should not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this period (see the Pregnancy section).
While taking Lisinopril/Hidroclorotiazida Teva-ratiopharm
If you develop any of the following symptoms, inform your doctor immediately:
At the beginning of treatment and/or during the dosage adjustment period, it may be necessary to increase the frequency of medical check-ups. Do not skip these visits even if you feel well. Your doctor will determine the frequency of medical check-ups.
Taking Lisinopril/Hidroclorotiazida with other medications
The concomitant use of other medications may affect the efficacy and safety of this medication. On the other hand, Lisinopril/Hidroclorotiazida Teva-ratiopharm may affect the safety and efficacy of other medications. Inform your doctor or pharmacist if you are using or have recently used other medications, including those purchased without a prescription, herbal products, and natural remedies. Remember to tell your doctor that you are taking Lisinopril/Hidroclorotiazida Teva-ratiopharm if they prescribe another medication during treatment or shortly after.
It is especially important to inform your doctor if you are taking:
Your doctor may need to adjust your dosage and/or take other precautions:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
Inform your doctor if you think you are (or may be) pregnant. Your doctor will usually advise you to stop taking lisinopril/hydrochlorothiazide before becoming pregnant or as soon as you know you are pregnant and will advise you to take another medication instead of Lisinopril/Hidroclorotiazida Teva-ratiopharm. Lisinopril/Hidroclorotiazida Teva-ratiopharm is not recommended in the early stages of pregnancy, and it should not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this period.
Breastfeeding
Inform your doctor if you are breastfeeding or plan to start breastfeeding. Lisinopril/Hidroclorotiazida Teva-ratiopharm is not recommended in breastfeeding mothers, and your doctor should choose another treatment if you want to breastfeed, especially if your baby is newborn or premature.
Driving and operating machinery
At the beginning of treatment, when the dosage is changed, or in combination with alcohol, Lisinopril/Hidroclorotiazida Teva-ratiopharm may have mild to moderate effects on your ability to drive or operate machinery that requires special attention. You should be aware that when driving vehicles or operating machinery, dizziness or fatigue may occur.
Athletes
Warning to athletes: This medication contains an active substance (hydrochlorothiazide) that may result in a positive test in a doping control.
Lisinopril/Hidroclorotiazida Teva-ratiopharm contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is one or two tablets per day. Your doctor will decide the dose you should take based on previous treatment with the separate medications lisinopril and hidroclorotiazida.
Renal Insufficiency
The dose depends on the degree of insufficiency. Follow your doctor's instructions.
Before Diuretic Treatment
Diuretic treatment should be suspended from 2 to 3 days before starting treatment with Lisinopril/Hidroclorotiazida Teva-ratiopharm. Follow your doctor's instructions.
Dose Change
Do not change the dose or stop taking the medication without consulting your doctor first.
If You Take More Lisinopril / Hidroclorotiazida Teva-ratiopharm Than You Should
In case of overdose or accidental ingestion, consult the Toxicological Information Service. Phone 91 562 04 20.
Immediately consult your doctor or the nearest hospital if you have taken more doses than you should (overdose). An overdose may cause a significant drop in blood pressure, which can lead to dizziness and mild headache. Symptoms may include shortness of breath, acceleration or slowing of the heart, palpitations, anxiety, or cough.
If You Forget to Take Lisinopril/Hidroclorotiazida Teva-ratiopharm
Do not take a double dose to compensate for the missed doses.
Resume the usual schedule.
If You Interrupt Treatment with Lisinopril/Hidroclorotiazida Teva-ratiopharm
Do not stop taking the medication without consulting your doctor first.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Very rare: may affect up to 1 in 10,000 people
Unknown: the frequency cannot be estimated from available data
If you notice any of the following side effects, stop taking lisinopril/hydrochlorothiazide and contact a doctor immediately:
Lisinopril
Common
Dizziness, headache, fainting, hypotension associated with symptoms (dizziness, weakness, blurred vision), dry cough, vomiting, diarrhea, renal dysfunction.
Uncommon
Mood changes, paresthesia, vertigo, taste alterations, sleep disturbances, depressive symptoms, hallucinations, tachycardia, palpitations, myocardial infarction or stroke (in high-risk patients possibly secondary to excessive hypotension), skin color change (pale or blue followed by redness) and/or numbness or tingling in the fingers of the hands and feet (Raynaud's syndrome), rhinitis, nausea, abdominal pain, indigestion, increased liver enzymes and bilirubin, itching with or without rash, skin rash, impotence, fatigue, asthenia, increased urea in the blood, increased serum creatinine, hyperkalemia.
Rare
Anemia, decreased hemoglobin, syndrome of inappropriate antidiuretic hormone secretion (SIADH), confusion, altered sense of smell, dry mouth, urticaria, psoriasis, hair loss, renal function disorders including renal insufficiency, uremia, development of breast tissue in men, hyponatremia.
Very rare
Poor bone marrow production, small number of platelets (thrombocytopenia), decreased white blood cell count (neutropenia, leucopenia), reduced number of white blood cells (agranulocytosis), making infections more likely, lymph node diseases, autoimmune diseases, where the body attacks itself, anemia, hemolytic anemia, bronchospasm, sinusitis, allergic alveolitis/neumonia eosinophilia, pancreatitis, allergic reaction in the small intestine (intestinal angioedema), liver insufficiency and cholestasis (including jaundice), hepatitis including necrosis, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, erythroderma, pemphigoid reactions, and exfoliative dermatitis, decreased or absent urine excretion, low blood sugar (hypoglycemia).
A complex symptom has been reported that may include one or more of the following: fever, vasculitis, myalgia, arthralgia/arthritis, positive antinuclear antibodies (ANA), elevated erythrocyte sedimentation rate, eosinophilia, and leucocytosis, rash, photosensitivity, and other dermatological manifestations may appear.
Unknown
Severe allergic reaction (anaphylactic/anaphylactoid reaction), flush.
Hydrochlorothiazide
Very rare
Acute respiratory distress (symptoms include severe difficulty breathing, fever, weakness, and confusion).
Unknown
Salivary gland inflammation, cancer of the skin and lips (non-melanoma skin cancer),leucopenia, neutropenia/agranulocytosis, thrombocytopenia, aplastic anemia, hemolytic anemia, bone marrow depression, anorexia, hyperglycemia, glucosuria, hyperuricemia, electrolyte imbalance (including hyponatremia, hypocalcemia, hypochloremic alkalosis, and hypomagnesemia), increased cholesterol and triglycerides, gout, restlessness, depression, sleep disturbances, loss of appetite, paresthesia, photosensitivity to light, yellow vision, transient blurred vision, decreased vision or eye pain due to increased pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma), vertigo, postural hypotension, necrotizing angitis (vasculitis, cutaneous vasculitis), respiratory distress (including pneumonitis and pulmonary edema), gastric irritation, diarrhea, constipation, pancreatitis, jaundice (intrahepatic cholestatic jaundice), photosensitivity reactions, rash, cutaneous lupus erythematosus, systemic lupus erythematosus, cutaneous lupus erythematosus reactions, urticaria, anaphylactic reactions, toxic epidermal necrolysis, muscle spasms, muscle weakness, renal dysfunction, interstitial nephritis, fever, weakness.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use, website:www.notificaRAM.esBy reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. By doing so, you will help protect the environment.
Lisinopril/Hidroclorotiazida Teva-ratiopharm 20/12,5 mg Composition
The active ingredients are: Lisinopril (as lisinopril dihydrate) and hydrochlorothiazide.
Each tablet contains 20 mg of lisinopril (as lisinopril dihydrate) and 12.5 mg of hydrochlorothiazide.
The other components are: mannitol, calcium hydrogen phosphate dihydrate, pregelatinized cornstarch without gluten, sodium croscarmellose, and magnesium stearate.
Appearance of the product and contents of the package
White, round, scored tablets with “LH” marked on the other side.
Lisinopril/Hidroclorotiazida Teva-ratiopharm 20/12,5 mg is available in PVC/PVDC/Aluminum blisters and polypropylene bottles with a low-density polyethylene screw cap and desiccant.
Each package contains blisters of 10, 28, 30, 50, 56, 60, 98, 100, 50 x 1 (perforated single-dose blister), 100 x 1 (perforated single-dose blister), and 500 x 1 (perforated single-dose blister) tablets.
Polypropylene bottles: 100 tablets.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Teva Pharma, S.L.U.
C/ Anabel Segura, 11, Edificio Albatros B, 1st floor,
Alcobendas, 28108 - Madrid
Responsible manufacturer
Merckle GmbH
Ludwig-Merckle-Street 3
89143 Blaubeuren (Germany)
This medicine is authorized in the member states of the European Economic Area with the following names:
Germany: | Lisinopril comp.- ratiopharm®20 mg/12,5 mg Tablets |
Luxembourg: | Lisinopril-ratiopharm comp. 20/12,5 mg |
Portugal: | Lisinopril and Hydrochlorothiazide ratiopharm 20 mg and 12.5 mg tablets |
Spain: | Lisinopril/Hidroclorotiazida Teva-ratiopharm 20/12,5 mg tablets EFG |
Last review date of this leaflet: July 2023
For detailed and updated information on this medicine, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.